IDiyas

For the Inventor, By the Inventor

Fanwood, NJ, United States of America

Shuwen He

USPTO Granted Patents = 34 

 

Average Co-Inventor Count = 6.1

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Edison, NJ (US) (2008 - 2019)
  • Fanwood, NJ (US) (2016 - 2023)

Company Filing History:

goldMedal27 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal6 out of 6 
 
Kallyope, Inc.
 patents
bronzeMedal2 out of 7 
 
Msd Italia S.r.l.
 patents
4. 1 out of 4,770 
 
Merck + Co., Inc.
 patents
5. 1 out of 97 
 
Albany Molecular Research, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...
Loading Chart...
34 patents (USPTO):
1. 12281114 - NK3 modulators and uses thereof (2025-04-21),
2. 12264171 - GPR40 agonists (2025-04-01),
3. 12264134 - Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-01),
4. 12152019 - Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-11-26),
5. 12091405 - Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-09-17),
6. 11851429 - AMPK activators (2023-12-26),
7. 11512065 - GPR119 agonists (2022-11-29),
8. 11478461 - [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-10-25),
9. 11407768 - AMPK activators (2022-08-09),
10. 11352320 - Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-06-07),
11. 11279702 - AMPK activators (2022-03-22),
12. 11267786 - [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-03-08),
13. 11072602 - Antidiabetic heterocyclic compounds (2021-07-27),
14. 11034661 - Substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors (2021-06-15),
15. 10988487 - Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-04-27),

Title: Innovator Spotlight: Shuwen He - A Pioneer in Biomedical Discoveries

Introduction:

Shuwen He is a prolific inventor based in Fanwood, NJ, with an impressive portfolio of 29 patents to his name. His groundbreaking work in developing AMPK activators and GPR119 agonists has paved the way for novel treatment approaches in conditions related to the gut-brain axis and metabolic disorders.

Latest Patents:

Among his latest patents, Shuwen He has focused on AMPK activators, which are instrumental in treating conditions associated with AMPK, particularly those tied to the gut-brain axis. Additionally, his work on GPR119 agonists has shown promise in addressing metabolic disorders like diabetes, obesity, and nonalcoholic steatohepatitis (NASH). These innovations include gut-restricted compounds that offer targeted therapeutic benefits to patients.

Career Highlights:

Shuwen He has made significant contributions to the field of biomedical research during his tenure at esteemed companies such as Merck Sharp & Dohme Corporation and Kallyope, Inc. His dedication to developing innovative pharmaceutical solutions has earned him recognition as a trailblazer in the industry.

Collaborations:

Throughout his career, Shuwen He has collaborated closely with accomplished professionals in the field, including Ravi P Nargund and Liangqin Guo. These collaborations have led to successful partnerships and the advancement of cutting-edge technologies in biomedicine.

Conclusion:

In conclusion, Shuwen He stands out as a visionary inventor who continues to push the boundaries of biomedical research with his groundbreaking patents and collaborations. His work not only showcases his expertise in developing novel treatments but also underscores his commitment to improving healthcare outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…